Changes to our trading names and address – MSD and Organon & Co. read more
Changes to our trading names and address
Please note that in 2021, MSD will be spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company known as Organon & Co.
Due to legal entity separation in advance of this spin off, we now have two UK registered businesses, MSD and Organon. Organon & Co. is a wholly owned subsidiary of Merck & Co., Inc. of Kenilworth, New Jersey, USA.
As a result of the future spin-off of Organon, as well as our head offices moving to London in early 2021, you will begin to see some changes to references to our products, contact details, materials and statements over the coming months.
MSD UK customer services
01992 452094
(During public holidays please contact our UK switchboard on 0208 1548000).
Emergency patient supply order form
Please click here to download an emergency patient supply order form (for use by UK healthcare professionals only).
Supply Status
|
Product Description
|
Supply Status
|
Estimated Resupply Date
|
|
INNOVACE®
10 mg Tablets
|
Intermittent Supply
|
|
|
ZERBAXA®
1 g/0.5 g powder for concentrate for solution for infusion
|
Out of Stock
|
2022
|
Notifications
Class 2 Medicines Recall: Merck Sharp & Dohme Limited, Zerbaxa 1g/0.5g Powder for Concentrate for Solution for Infusion, EL (20)A/60
Information can be found here: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-merck-sharp-and-dohme-limited-zerbaxa-1g-slash-0-dot-5g-powder-for-concentrate-for-solution-for-infusion-el-20-a-slash-60
Zoely® 2.5 mg/1.5 mg film-coated tablets
As of 1st July 2020, Zoely® 2.5 mg/1.5 mg film-coated tablets is no longer supplied by MSD - refer to Theramex for more information.
COVID-19
We continue to track the COVID-19 outbreak closely and are focused on the safety of our employees and their families, continuity of supply and clinical trials, and supporting communities affected by this outbreak. Our thoughts are with the people of all affected areas.
Information about Esmeron® (rocuronium bromide) 10 mg/ml solution for injection
In relation to the COVID 19 crisis, we are experiencing a substantial increase in demand for our product Esmeron globally and the Company is actively engaged in increasing supply. To help the supply of rocuronium bromide to the UK market, a quantity of Esmeron which was packaged for Australia has been made available to the UK, as an interim measure.
The Medicines and Healthcare Regulatory Agency (MHRA) have approved the use of this supply for the UK.
The details of the batches that will be supplied are detailed below:
|
Batch number
|
Expiry date
|
|
T011923
|
Feb 2023
|
|
T011924
|
Feb 2023
|
|
T012129
|
Feb 2023
|
|
T012763
|
Feb 2023
|
|
T012764
|
Feb 2023
|
|
T014251
|
Feb 2023
|
|
T014929
|
Mar 2023
|
|
T014958
|
Mar 2023
|
|
U003785
|
Nov 2023
|
A letter has been distributed to describe the differences in the packaging and that a PIL is not included in the pack, this letter can be found here.
Discontinuations
- Product Description
- Diprosone 0.05% w/w Ointment 100 gm
- Diprosone 0.05% w/w Cream 30 gm
- Rebetol 200 mg hard capsules
- Restandol® Testocaps™ 40 mg capsule
- Zispin SolTab® 15 mg orodispersible tablets
- Zispin SolTab® 30 mg orodispersible tablets
- Zispin SolTab® 45 mg orodispersible tablets
- Zocor® 80 mg film-coated tablets
This page is intended for use by UK healthcare professionals only. Trademarks appearing on this website are owned, licensed to, promoted or distributed by Merck & Co., Inc., Kenilworth, NJ, USA, its subsidiaries or affiliates, except as noted.
Job code: GB-NON-04107Date of preparation: March 2021